Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus.

Autor:	Brüggen MC; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.; Faculty of Medicine, University of Zurich, Zurich, Switzerland.; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France., Walsh S; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Dermatology, King's College Hospital, London, England, United Kingdom., Ameri MM; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.; Faculty of Medicine, University of Zurich, Zurich, Switzerland.; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland., Anasiewicz N; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland., Maverakis E; Department of Dermatology, University of California, Davis, Sacramento, California., French LE; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.; Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida., Ingen-Housz-Oro S; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Dermatology, Henri Mondor University Hospital, University of Paris-Est Créteil, Créteil, France.; Toxic Bullous Dermatoses TOXIBUL Reference Center, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.; Univ Paris Est Créteil EpiDermE, Créteil, France., Abe R; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Ardern-Jones M; Department of Dermatology, Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, England, United Kingdom., Assier H; Department of Dermatology, Henri Mondor University Hospital, University of Paris-Est Créteil, Créteil, France., Barbaud A; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique, AP-HP Sorbonne Universite, Tenon Hospital, Department of Dermatology and Allergology, Paris, France., Bensaid B; Department of Dermatology, Lyon Natecia Hospital, Lyon, France., Bernal W; Liver Intensive Therapy Unit, King's Critical Care, King's College Hospital, London, England, United Kingdom., Bernier C; Department of Dermatology, University Hospital Nantes, Nantes, France., Brassard A; Department of Dermatology, University of California, Davis, Sacramento, California., Brezinová E; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Dermatovenereology, St Anne's Faculty Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Cabañas R; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.; PIELenRed Consortium, Madrid, Spain.; Center for Biomedical Research Network on Rare Diseases (CIBERER U754), Madrid, Spain., Cardones A; Department of Dermatology, University of Kansas, Kansas City., Chu CY; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Chua SL; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Dermatology, University of California, San Francisco., Descamps V; Department of Dermatology, Bichat-Claude Bernard Hospital, Paris Diderot University, Paris, France., Didona B; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Center of Rare Diseases IDI-IRCCS, Rome, Italy., Divito SJ; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Dodiuk-Gad R; Department of Dermatology, Emek Medical Center, Afula, Israel.; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel., Elman S; Department of Dermatology, Miller School of Medicine, University of Miami, Miami, Florida., Gaspar K; Department of Dermatology, University of Debrecen, Debrecen, Hungary., Mortz CG; Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, Odense, Denmark., Hama N; Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Lee HY; Department of Dermatology, Singapore General Hospital, Singapore, Singapore., Horváth B; Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Jörg L; Division of Allergology and Clinical Immunology, Department of Pneumology and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Kaffenberger BH; Department of Dermatology, The Ohio State University, Columbus, Ohio., Kucinskiene V; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences (LUHS), Hospital of LUHS Kauno Klinikos, Kaunas, Lithuania., Lebrun-Vignes B; Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France., Lehloenya RJ; Department of Paediatric Dermatology, Colentina University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Meyersburg D; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University, Salzburg, Austria., Micheletti R; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Images in Dermatology Editor, JAMA Dermatology., Milpied B; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Toxic Bullous Dermatoses TOXIBUL Reference Center, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.; Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France., Miyagawa F; Department of Dermatology, Nara Medical University, Kashihara, Japan., Mostaghimi A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Nägeli M; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland., Naldi L; Department of Dermatology, Ospedale San Bortolo, Vicenza, Italy., Oppel E; Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany., Phillips EJ; Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee., Pirani T; Liver Intensive Therapy Unit, King's Critical Care, King's College Hospital, London, England, United Kingdom., Ranki A; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland., Mälkönen T; Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland., Rosenbach M; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Salavastru C; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Paediatric Dermatology, Colentina University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Staumont-Salle D; CHU Lille, Department of Dermatology, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France., Sandberg H; Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland., Setterfield J; Department of Oral Medicine, Guy's and St Thomas' NHS Foundation Trust, London, England, United Kingdom., Shinkai K; Department of Dermatology, University of California, San Francisco.; Editor, JAMA Dermatology., Shiohara T; Department of Dermatology, Kyorin University School of Medicine, Mitaka, Japan., Soria A; Department of Dermatology and Allergology, Tenon Hospital, Sorbonne Universite, Paris, France., Tartar D; Department of Dermatology, University of California, Davis, Sacramento, California., Tiplica GS; ToxiTEN group, European Reference Network for Rare Skin Diseases (ERN-Skin), Paris, France.; Department of Dermatology II, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Traidl S; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.; Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany., Vorobyev A; Department of Dermatology, University Hospital Lübeck, Lübeck, Germany., von Wachter C; Faculty of Medicine, University of Zurich, Zurich, Switzerland., Worswick S; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles., Cho YT; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Jazyk:	angličtina
Zdroj:	JAMA dermatology [JAMA Dermatol] 2024 Jan 01; Vol. 160 (1), pp. 37-44.
DOI:	10.1001/jamadermatol.2023.4450
Abstrakt:	Importance: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. To our knowledge, there is no international consensus on its severity assessment and treatment. Objective: To reach an international, Delphi-based multinational expert consensus on the diagnostic workup, severity assessment, and treatment of patients with DRESS. Design, Setting, and Participants: The Delphi method was used to assess 100 statements related to baseline workup, evaluation of severity, acute phase, and postacute management of DRESS. Fifty-seven international experts in DRESS were invited, and 54 participated in the survey, which took place from July to September 2022. Main Outcomes/measures: The degree of agreement was calculated with the RAND-UCLA Appropriateness Method. Consensus was defined as a statement with a median appropriateness value of 7 or higher (appropriate) and a disagreement index of lower than 1. Results: In the first Delphi round, consensus was reached on 82 statements. Thirteen statements were revised and assessed in a second round. A consensus was reached for 93 statements overall. The experts agreed on a set of basic diagnostic workup procedures as well as severity- and organ-specific further investigations. They reached a consensus on severity assessment (mild, moderate, and severe) based on the extent of liver, kidney, and blood involvement and the damage of other organs. The panel agreed on the main lines of DRESS management according to these severity grades. General recommendations were generated on the postacute phase follow-up of patients with DRESS and the allergological workup. Conclusions and Relevance: This Delphi exercise represents, to our knowledge, the first international expert consensus on diagnostic workup, severity assessment, and management of DRESS. This should support clinicians in the diagnosis and management of DRESS and constitute the basis for development of future guidelines.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu